Gentian violet is banned or restricted in several countries because it is a carcinogen. In June 2019, Health Canada pulled all gentian violet drug products from the market after concluding there is no safe level of exposure and that any use of the substance poses a cancer risk. The decision followed decades of accumulating evidence linking the dye to tumor growth in multiple organs.
The Cancer Risk Behind the Ban
Gentian violet, also known as crystal violet, is a deep purple dye that was once a go-to treatment for fungal infections, skin conditions, and oral thrush. It doubled as an industrial dye in textiles, paints, and printing ink. The same chemical properties that make it useful also make it dangerous.
The most significant evidence comes from a large-scale lifetime feeding study in mice. Researchers gave 1,440 mice varying doses of gentian violet in their food and tracked them over their natural lifespan. The results were clear: liver cancer (hepatocellular carcinoma) increased in a direct dose-response pattern, meaning higher doses produced more tumors. Males showed elevated liver cancer rates at 24 months, while females showed them at both 18 and 24 months. But the damage wasn’t limited to the liver. Female mice also developed tumors of the bladder, uterus, ovaries, and a gland behind the eye, along with ovarian atrophy and abnormal red blood cell production in the spleen.
These findings established gentian violet as a carcinogen at multiple organ sites. The substance also acts as a mitotic poison, meaning it disrupts cell division, and is classified as both genotoxic (damaging DNA) and clastogenic (breaking chromosomes). It is now formally regarded as a biohazard substance. Health Canada’s position, which drove the 2019 ban, is that because gentian violet causes cancer through mechanisms with no safe threshold, even small exposures are a concern.
Serious Risks for Infants
Beyond cancer, gentian violet poses immediate physical dangers, especially to babies. For decades, parents and even some healthcare providers used a 1% or 2% solution painted inside a baby’s mouth to treat oral thrush, a common yeast infection. That practice has caused documented harm.
Gentian violet is toxic to mucous membranes. In infants treated for thrush, it has caused painful oral ulceration, sometimes severe enough to partially obstruct the airway. In one case, a two-week-old breastfed infant was given a 1% gentian violet solution for oral thrush. The parents initially stopped after one day because the baby seemed to have airway discomfort. When they restarted it at a higher frequency (four times daily), the infant developed a cough and difficulty feeding within a day and had to be hospitalized and intubated. These are not rare side effects of misuse; they occurred at concentrations that were once considered standard.
Where It Still Shows Up
Gentian violet hasn’t disappeared entirely. In some countries, it remains available over the counter or through compounding pharmacies, particularly in parts of Africa and Asia where it is still used for wound care and fungal infections. In the United States, the FDA has not issued a full ban equivalent to Canada’s, but gentian violet products have largely fallen out of mainstream medical use. Its industrial applications in textile dyeing, biological staining in labs, and as an additive in poultry feed to prevent fungal growth also persist in various regions, raising environmental concerns because the compound breaks down very slowly and lingers in water and soil.
What Replaced It
Modern antifungal treatments are safer and more effective than gentian violet ever was. For mild oral thrush, current guidelines from the Infectious Diseases Society of America recommend miconazole (a muco-adhesive tablet placed on the gums once daily for 7 to 14 days) or nystatin, available as a liquid suspension or pastilles used four times daily for the same period. The World Health Organization also endorses nystatin as an alternative for treating oral yeast infections in both children and adults with HIV.
For moderate to severe cases, oral fluconazole taken daily for 7 to 14 days is the standard treatment. Fluconazole-resistant infections can be managed with other prescription antifungals. All of these options target the fungal infection without coating the mouth in a carcinogenic dye or risking mucosal damage. If you still have gentian violet in your medicine cabinet from years past, there is no medical reason to use it when these alternatives exist.